ManTRa Diagnostics develops a pan-cancer next-generation sequencing (NGS) panel that utilizes tumor-site-specific gene expression signatures to measure hypoxia in solid tumors. This technology enables clinicians to identify patients most likely to benefit from targeted therapies, addressing the challenge of treatment resistance associated with low oxygen levels in tumors.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors often exhibit varying levels of oxygenation (hypoxia), which is associated with resistance to radiation, chemotherapy, and immunotherapy, leading to poor prognosis and increased likelihood of recurrence. Current clinical practice lacks routine methods to measure tumor hypoxia, hindering personalized treatment strategies.
Solution
ManTRa Diagnostics offers a pan-cancer next-generation sequencing (NGS) panel, the ManTRa DX test, designed to measure tumor-site-specific gene expression signatures related to hypoxia in solid tumors. This Laboratory Derived Test (LDT) provides clinicians with a biomarker to identify patients who are most likely to benefit from targeted therapies and enables the stratification of patients for clinical trials. By assessing the hypoxic status of a tumor, the ManTRa DX test facilitates personalized care plans and the research of new combination treatments, ultimately improving patient outcomes. The test integrates seamlessly within clinical workflows, requiring no additional intervention or biopsy.
Target Audience
The primary audience includes clinicians, pharmaceutical companies, university/hospital labs, and Key Opinion Leaders (KOLs) involved in cancer research and treatment.
Features
- Pan-cancer NGS targeted RNA-signature panel detects hypoxia in multiple cancers (bladder, sarcoma, head and neck and prostate).
- Delivered as an ISO regulated
- fee for service Laboratory Derived Test (LDT).
- Provides tumor-site-specific gene expression signatures to assess hypoxia.
- Enables evaluation of hypoxia’s impact on treatment efficacy.
- Facilitates stratification of patients according to suitability for specific therapies.
- Aids in refining clinical trial cohorts.